2 results
Approved WMOCompleted
Primary ObjectiveThe primary objective is to investigate the PK of the MMF * the main metabolite of DMF * following administration of a delayed-and slow-release tablet formulation (FP187-GC) and the marketed enteric-coated delayed release…
Approved WMOCompleted
Primary: Document and characterize the severe toxicity and clinical activity of the recNY-ESO-1 + AS15 ASCI in patients with NY-ESO-1-positive metastatic cutaneous melanoma.Secondary: Document and characterize additional clinical indicators of…